The European Medicines Agency’s (EMA) safety committee has launched a review of medicines containing semaglutide following concerns about an increased risk of developing a rare eye disease, Naion. This is what a press release states.
The decision was made with reference to two recent observational studies. At the same time, she points out that two other recent observational studies do not suggest an increased risk.
Semaglutide, a GLP-1 receptor agonist, is the active ingredient in some drugs used to treat diabetes and obesity, including Novo Nordisk’s trio Wegovy, Ozempic and Rybelsus.
-Naion is a condition caused by decreased blood flow to the optic nerve of the eye, resulting in potential damage to the nerve, which can lead to vision loss in the affected eye.
Senegal
